Nearly 400 physicians, researchers, and other health care professionals traveled to Milwaukee for our 10th International Symposium on Functional Gastrointestinal (GI) Disorders in April. Leaders in the GI field presented cutting edge knowledge on functional GI and motility disorders and treatments to other professionals who treat patients with these conditions across the world. In the last issue of Digestive Health Matters we highlighted three topics that were discussed at the meeting

What we Know: An integrated understanding of the functional disorders; Global Epidemiology: How widespread are they; and New Concepts in Pathophysiology of Functional GI Disorders: Causes and mechanisms. Here, we share three more interesting areas that were covered during the three day conference. 

Children and Functional GI and Motility Disorders

"Children are not small adults and adults are not big children." Christophe Faure, M.D., Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada

According to research published in 2009, almost four billion dollars were spent annually in the U.S. just on treatment of childhood constipation. Based on Rome III criteria, 87 percent of these kids had functional constipation.

Early painful experiences, trauma, and social learning can influence symptom presentation of functional gastrointestinal and motility disorders (FGIMDs) in children. Miranda van Tilburg, Ph.D., University of North Carolina, Chapel Hill, NC, reviewed painful experiences during infancy which can impact normal nerve growth and increased risk for developing FGIMDs. During these early years, the part of the central nervous system that controls pain, is maturing.

However, inflammation and painful experiences, such as injuries to the GI tract, events associated with abdominal pain, and learned social behaviors, can cause changes to the pain control system.

The good news is that researchers are getting a handle on what is going wrong in the gut and on a cellular level. These insights may offer the basis for treatment strategies. New research studies have found differences in microorganisms in the gut (microbiota) of children with irritable bowel syndrome (IBS).

The intestinal flora makeup of kids with diarrhea prominent IBS (IBS-D) and abdominal pain was different than that of kids without functional gastrointestinal conditions.


Diet can affect your microbiota. These charts represent the differences in the microbiota of children in Italy (left) versus in Africa (right), who have very different types of diets.

Difficult to Treat Heartburn

Gastroesophageal reflux disease (GERD) is a condition which develops when the back-flow (reflux) of acidic or non-acidic stomach contents causes troublesome symptoms and/or complications. The most frequent symptom of GERD is heartburn. Proton pump inhibitors (PPIs) are drugs that work by limiting acid secretion in the stomach. They are often prescribed to treat symptoms of GERD.


A pictogram used to help diagnose patients with heartburn or GERD. Patients are asked, “How often did you feel a burning pain in the red area shown in the picture – that is, behind the breastbone?”

But why do some people still experience persistent heartburn while taking a PPI? When there is no response to a PPI taken once daily, it may be due to non-erosive reflux disease (not caused by acidic reflux) or functional heartburn. When there’s no response to a PPI taken twice daily, it is probably functional heartburn.

10th symposium chartOf those who take a PPI once per day, about 38% still experience symptoms. Of those, about 62% experience their symptoms mostly at night.

"There are various underlying mechanisms that can lead to proton-pump inhibitor failure and some may even overlap in the same patient. The functional heartburn group provides most of the PPI failure (twice daily patients)," notes Ronnie Fass, M.D., MetroHealth Medical Center, Cleveland, OH.

Unfortunately, upper endoscopy (a test to see inside the upper GI tract) has a limited role in evaluating persons who failed PPI once or twice daily. A pH test that measures acidic or non-acidic reflux in the esophagus provides the best information in evaluating individuals with chronically unmanageable heartburn on treatment.

Lifestyle and dietary modifications are the first line of treatment. Other medications may help reduce esophageal pain, including low-dose antidepressants. Acupuncture and cognitive behavioral therapy may also be helpful in controlling the symptoms of heartburn that has not responded to other treatments.

Food Allergies and Sensitivities

"How gluten sensitivity contributes to FGIDs remains unclear but multiple mechanisms are implicated." Shelia E. Crowe, M.D., University of California, San Diego, San Diego, CA

For many IBS patients, food choices provoke symptoms. Research supports an association between symptoms and specific dietary components such as tryptophan and gluten. Too much or too little tryptophan can influence both levels of anxiety and GI symptoms. The link between gluten sensitivity and GI symptoms in classic celiac is very clear. IBS patients may not have celiac disease, but gluten may still induce their IBS symptoms.

Celiac disease can coexist with or even mimic IBS and other FGIMDs for some people. For others, the mechanism of gluten sensitivity in IBS remains unclear. Though we do not have direct evidence, research suggests a link between gluten and IBS symptoms.

Scientists found that immunity markers present in gluten sensitivity may not be altered in celiac disease. Australian researchers discovered that a group of white blood cells (macrophages) behaved abnormally after gluten ingestion. They also found that a protein found in gluten called gliadin increased the number of these cells. Putting it all together, they believe that partially digested fragments of gluten trigger this immune response which in turn provokes dysfunction in the gut.


Symposium Report and resources

The Need for More Research - How You Can Help

IFFGD participates in and encourages support of scientific inquiry and research. Although the need has been demonstrated, functional GI disorder research remains severely underfunded.

There are a growing number of clinicians and investigators who are striving to learn more about the functional gastrointestinal disorders. They need research funding. You can help. Working together, we can change the way these disorders are viewed, managed and treated. To know more about funding needs, visit: Need for Funding Research and How to Make a Difference.

Make a Donation for Research

Nancy J. Norton, IFFGD Founder
Ceciel T. Rooker, IFFGD President
Advisory Board
Officers and Board of Directors
Our Mission
Awareness Activities & Accomplishments
Public Education & Awareness
Professional Education & Awareness
Year in Review
Advocacy Activities
Legislative Successes
FGIMD Act (Functional Gastrointestinal and Motility Disorders Research Enhancement Act)
Congressional Testimony
FDA and Other Testimony
Written Comments to FDA December 30, 2019
Written Comments to FDA October 15, 2019
Written Comments to SSA September 23, 2019
Written comments to FDA April 30, 2019
Written Comments to SSA February 15, 2019
Written Comments to HHS February 5, 2019
Written Comments to DoD December 13, 2018
Written Comments to FDA October 18, 2018
Written Comments to FDA October 17, 2018
Written Presentation to FDA September 12, 2017
Written Comments to FDA June 29, 2015
Oral Comments to FDA May 11, 2015
Comments to FDA July 16th, 2014
Written Comments to Noridian October 24, 2013
Testimony to FDA October 25, 2012
Testimony to FDA September 12, 2012
Testimony to FDA December 13, 2011
Testimony to FDA December 2, 2010
Testimony to FDA April 23, 2002
Comments to FDA November 9, 2000
Testimony to FDA June 27, 2000
Testimony to FDA June 26, 2000
Capitol Hill Advocacy Day
National Institutes of Health (NIH)
IFFGD Research Awards
IFFGD Symposium reports
2013 Professional Symposium
10th Symposium Report
10th Symposium Audio Recordings
More from the 10th Symposium on FGIDs
2011 Professional Symposium
9th Symposium Report
2009 Professional Symposium
2007 Professional Symposium
7th Symposium Report
2005 Professional Symposium
6th Symposium Report
2003 Professional Symposium
5th Symposium Report
2002 Conference - Advancing the Treatment of Incontinence
Corporate Support
Our Research Funding Needs
IFFGD Standards for Collaboration
Industry Council
Code of Ethics
Contact Us
Media Contact
Ambassadors Program
2019 Ambassadors

Funding Research

IFFGD2018Breakfast 002 cropped

IFFGD funds research that helps to shape science and scientific advancement, and improve quality of life for people affected by chronic digestive disorders.

IFFGD Research Awards

Professional Education

Research funding needs